论文部分内容阅读
顺铂(Cisplatin)是顺式二氯二氨铂 (Ⅱ)(Cis-dichloro-diaminoplatinum Ⅱ,Cis- DDP;CPDD;NSC-119875)的简称。1969年Rosenberg首次发现顺铂有强烈的抗癌活性。其后,一些国家对其基础理论与临床应用进行了广泛的研究,已引起医药界的重视。1974年以来,我国辽宁、山东、广东等地也相继开展了顺铂合成、抑癌实验和临床应用等研究。目前,在更多的地方以协作组的形式进行临床试验。国内外的研究成果显示,以顺铂为代表的铂络合物是一组抗癌谱广、抗癌作用强、与多种抗肿瘤药有协同作用的颇有前途的抗癌新药。本文仅就顺铂的药理与临床作简要介绍,以供参考。
Cisplatin is an abbreviation of Cis-dichloro-diaminoplatinum II (Cis-DDP; CPDD; NSC-119875). Rosenberg first discovered in 1969 that cisplatin had a strong anticancer activity. Since then, some countries have carried out extensive research on their basic theories and clinical applications, which has attracted the attention of the medical community. Since 1974, studies on cisplatin synthesis, tumor suppressor experiments and clinical applications have also been carried out in Liaoning, Shandong, and Guangdong. At present, clinical trials are conducted as collaborative groups in more places. The research results at home and abroad show that the platinum complex represented by cisplatin is a promising new anti-cancer drug with a broad spectrum of anticancer activity, strong anticancer activity, and synergy with many antitumor drugs. This article only briefly introduces the pharmacological and clinical aspects of cisplatin for reference.